At a median follow-up of 15.9 months, the median duration of response was not reached.
The “myTcell” app is expected to be released in the United States in 2022.
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
The findings of this study prompted a change in clinical practice.
Outcomes were similar to those seen in the ZUMA-2 trial.
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.